Response of VEGF and AT-II to HCG in PCOS

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

This research is to investigate the response of vascular active factors, vascular endothelial growth factor (VEGF) and angiotensin-Ⅱ (AT-Ⅱ) to ovary stimulation during 24h in patients with polycystic ovary syndrome (PCOS).Controled prospective clinical study involved 60 women undergoing in vitro fertilization. Fifty-two patients with PCOS and 8 control cases were stimulated with human chorionic gonadotropin (HCG) during the early follicular phase of the menstrual cycle (4st to 7th days of the cycle).The blood was sampled before the injection (0 hour) and at the 3, 6, 12, 18 and 24 hours points after the stimulation. VEGF, AT-Ⅱ were measured by radioimmunoassay.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Nanjing University School of Medicine
• Treatments: Angiotensin II; Angiotensinogen; Chorionic Gonadotropin; Endothelial Growth Factors

Criteria

Inclusion Criteria:

• A total of 60 women were recruited and divided into four groups by Rotterdam criteria according to three typical characters:

1. biochemical characteristics of hyperandrogenism (HA)

2. chronic anovulation

3. polycystic ovary morphology (PCO).

Exclusion Criteria:

• All women were matched for age (<35 yr).

• All subjects were screened, and no other endocrine disturbances (thyroid, adrenal) or medical illnesses were found.

• All the patients did not have any hormonal preparation during the 3 months preceding the study.